期刊文献+

丙戊酸钠和亚砷酸对Molt-4细胞的协同抑制作用

Synergistic antitumor effects of VPA and As2O3 on Molt-4 cells in vitro
原文传递
导出
摘要 目的 观察丙戊酸钠(VPA)以及亚砷酸(As2O3)对人类急性T细胞白血病细胞株Molt-4增生、分化和细胞周期的影响以及二者的协同作用.方法 用MTT法观察细胞生长曲线及药物对细胞增生的抑制作用,流式细胞仪检测给药前后DNA含量变化等方法,观察了As2O3和VPA对Molt-4细胞体外抗癌的协同作用.结果 VPA和As2O3均可明显抑制细胞增生,VPA对Molt-4细胞抑制率为50%的浓度即JC50卯为4.904 mmol/L;As2O3的IC50为9.925μmol/L;当二者联用时在体外有相加作用(Q值均>0.85),在5 mmol/L VPA与10 μmol/L As2O3联用时抑制率达(70.31±2.54)%.流式细胞术检测示经不同浓度VPA处理后G1期细胞由28.21%增加至71.89%,S期细胞由71.75%减低至9.49%.结论 VPA和As2O3均可明显抑制细胞增生,两者合用有协同相加作用,其机制有待进一步研究. Objective The study was purposed to investigate the synergistic antitumour effects of sodium valproate (VPA) and As2O3 on the proliferation, differentiation and cell cycle of Moh-4 cell in vitro.Methods Cell viability and growth curve were assessed by the MTT assay and the DNA content of Molt-4cell was analyzed by flow cytometry after exposure 36 h to VPA and As2O3. Results The results indicated that the changes of the growth curve and MTT assay showed their inhibition of proliferation to Moh-4 cells.The 50 % inhibition rate of VPA and As2O3 were 4.904 mmol/L and 9.925 μmol/L respectively. There was an addition effect with the combination of the two drugs (values of Q >0.85). The inhibition rate was up to (70.31±2.54)% when exposing to 5.0 mmol/L VPA combinating with 10.0 μmol/L As2O3. Flow cytometry showed that the percentage of Molt-4 ceils in G1 phase increased from 28.21% to 71.89 % and the cells in S phase decreased from 71.75 % to 9.49 % after 36 h culture of VPA. Conclusion It was found that the combinations of VPA and As2O3 for 48 h increased inhibition rate to a greater extent than occurred for cell treated with either compound alone. The mechanism needed to be further studied.
出处 《白血病.淋巴瘤》 CAS 2008年第2期-,共4页 Journal of Leukemia & Lymphoma
基金 漳州市科技计划,福建省自然科学基金
  • 相关文献

参考文献10

  • 1傅海英,沈建箴.多发性骨髓瘤患者p16基因甲基化及砷剂诱导去甲基化的研究[J].中华内科杂志,2005,44(6):411-414. 被引量:14
  • 2佟红艳,林茂芳.三氧化二砷诱导人骨髓增生异常综合征细胞株MUTZ-1细胞p15INK4B基因表达的研究[J].中华血液学杂志,2002,23(12):638-641. 被引量:17
  • 3Gurvich N,Tsygankova OM,Meinkoth JL. Histone deacetylase is a target of valproic acid-mediated cellular differentiation[J].Cancer Research,2004,(03):1079-1088.doi:10.1158/0008-5472.CAN-03-0799.
  • 4Gottlicher M. Valproic acid:an old drug newly discovered as inhibitor of histone deacetylases[J].Annals of Hematology,2004,(Z1):S91-S92.
  • 5金正均.合并用药中的相加[J]中国药理学报(英文版),1980(02):70.
  • 6Jaffe LF. Epigenetic theories of cancer initiation[J].Advances in Cancer Research,2003,(0):209-230.doi:10.1016/S0065-230X(03)90007-8.
  • 7Kawagoe R,Kawagoe H,Sano K. Valproin acid induces apoptosis in human leukemia cells by stimulating both caspases-dependent and independent apoptotic signaling pathways[J].Leukemia Research,2002,(05):495-502.doi:10.1016/S0145-2126(01)00151-5.
  • 8Sasakawa Y,Naoe Y,Inoue T. Effects of FK288,a novel histone deacetylase inhibitor,on human lymphoma U-937 ceils in vitro and invivo[J].Biochemical Pharmacology,2002,(07):1079-1090.doi:10.1016/S0006-2952(02)01261-3.
  • 9Tang R,Faussat AM,Majdak P. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1[J].Leukemia:Official Journal of the Leukemia Society of America Leukemia Research Fund U K,2004,(07):1246-1251.
  • 10Kundgen A,Strupp C,Aivado M. Treatment of myelodysplastic syndromes with valproie acid aline or in combination with all-transretinoic acid[J].Blood,2004,(05):1266-1269.doi:10.1182/blood-2003-12-4333.

二级参考文献15

  • 1Macc JM, Wang LJ. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene P53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res, 1997, 386: 263-277.
  • 2Steube KG, Gignac SG, Hu ZB, et al. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line Mutz-1. Leuk Lymphoma, 1997, 25: 345-363.
  • 3Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci U S A, 1996,93:9821-9826.
  • 4Toyota M, Kopecky KJ, Yoyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood, 2001,97: 2824-2829.
  • 5Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood, 2001, 97: 1172-1179.
  • 6Tian HF, Tang JL, Tsay W, et al. Methylation of the P15INK4b gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukemia transformation. Br J Haematol, 2001, 112:148-154.
  • 7Lin C, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res, 2001,61:4238-4243.
  • 8Ahlumwalisa A, Hurteau JA, Bigsby RM, et al. DNA methylation of ovarian cancer. Ⅱ. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol, 2001, 82:299-304.
  • 9Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 1975, 36: 842-854.
  • 10Herman JG, Graff JR, Myohanen S, et al. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996,93:9821-9826.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部